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Abstract
Aims: The GLOBAL LEADERS trial is a superiority study in patients undergoing percutaneous coronary 
intervention, with a uniform use of Biolimus A9-eluting stents (BES) and bivalirudin. GLOBAL LEADERS 
was designed to assess whether a 24-month antithrombotic regimen with ticagrelor and one month of ace-
tylsalicylic acid (ASA), compared to conventional dual antiplatelet therapy (DAPT), improves outcomes.
Methods and results: Patients (n >16,000) are randomised (1:1 ratio) to ticagrelor 90 mg twice daily 
for 24 months plus ASA ≤100 mg for one month versus DAPT with either ticagrelor (acute coronary syn-
drome) or clopidogrel (stable coronary artery disease) for 12 months plus ASA ≤100 mg for 24 months. 
The primary outcome is a composite of all-cause mortality or non-fatal, new Q-wave myocardial infarc-
tion at 24 months. The key safety endpoint is investigator-reported class 3 or 5 bleeding according to the 
Bleeding Academic Research Consortium (BARC) definitions. Sensitivity analysis will be carried out to 
explore potential differences in outcome across geographic regions and according to specific angiographic 
and clinical risk estimates.
Conclusions: The GLOBAL LEADERS trial aims to assess the role of ticagrelor as a single antiplatelet 
agent after a short course of DAPT for the long-term prevention of cardiac adverse events, across a wide 
spectrum of patients, following BES implantation. 
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Background
The optimum duration of dual antiplatelet therapy (DAPT) after 
coronary drug-eluting stent placement remains uncertain. Practice 
guidelines recommend DAPT for at least 12 months following 
drug-eluting stent (DES) implantation in patients with acute coro-
nary syndromes (ACS), and for at least six months in patients with 
stable coronary artery disease (SCAD) in Europe1,2. The evidence 
base supporting the “at least 12 months recommendation” in ACS 
patients is weak, and some randomised controlled trials actually 
provide evidence suggesting that the risks of prolonging DAPT 
beyond six to 12 months outweigh the potential benefits3-6.
Conversely, recent trials on DAPT duration have shown a clear 
reduction in rates of stent thrombosis and major adverse cardio-
vascular events in patients free from bleeding or ischaemic events 
at 12 months who continued the DAPT regimen up to 30 months. 
While an increase in bleeding risk was a potentially anticipated 
finding, the observation of a possible increase of non-cardiovas-
cular mortality in patients prolonging DAPT beyond 12 months 
remains a matter of concern7-9. For more than a decade, the main-
stay of DAPT has been the combination of the weak cyclo-oxy-
genase-1 inhibitor acetylsalicylic acid (ASA), and clopidogrel. 
However, the inherent limitations of clopidogrel are well recog-
nised, including a slow onset of action and a variable response10-13. 
Prasugrel and ticagrelor provide superior protection against ischae-
mic adverse events compared with clopidogrel in patients following 
an ACS undergoing percutaneous coronary intervention (PCI)14-16. 
Notwithstanding this, both drugs incur an increased risk of spon-
taneous bleeding. As of today, these drugs have not been tested 
in patients undergoing elective PCI for SCAD, or as monotherapy 
(i.e., without ASA).
Ticagrelor is a reversible oral P2Y12 receptor antagonist that 
does not require metabolic activation17. The inter-individual vari-
ability of platelet inhibition is low17. In the Platelet Inhibition and 
Patient Outcomes (PLATO) trial there was a hint of an attenua-
tion of the treatment effect of ticagrelor by an ASA maintenance 
dose above 150 mg once daily18,19. Given the fact that strong P2Y12 
receptor inhibition may also provide inhibition of the COX-1 path-
way, it remains possible that ticagrelor monotherapy maintains 
efficacy compared to the combined use of aspirin and ticagrelor, 
while improving safety (i.e., a reduction of spontaneous/gastroin-
testinal bleeding)20.
Finally, during long-term follow-up, optimisation of secondary 
prevention and overall medical management are at least as impor-
tant as the selection of which stent to use21-24. A potent consistent 
and reversible P2Y12 receptor antagonist such as ticagrelor may 
provide superior efficacy with similar or improved safety com-
pared to the current standard regimen24.
Study objectives
GLOBAL LEADERS (ClinicalTrials.gov, NCT01813435) was 
designed to determine the benefits and risks of an antithrombotic 
regimen using ticagrelor combined with acetylsalicylic acid (ASA) 
for one month and alone for 23 months, compared to conventional 
DAPT in patients on bivalirudin undergoing biolimus-eluting stent 
implantation.
Substudies are planned to enhance understanding of the 
treatment effects and refine modelling of outcomes (Online 
Appendix 1). The SYNTAX score (SX score) for each patient will 
be calculated by scoring all coronary lesions with a DS ≥50%, 
in vessels ≥1.5 mm, using the SX score algorithm (available at 
www.syntaxscore.com)25. The GRACE risk score at index admis-
sion will be calculated for all patients suffering an acute coronary 
syndrome (ACS)26.
Study oversight
GLOBAL LEADERS is an investigator-initiated and scientifically 
driven trial sponsored by the European Clinical Research Institute 
(www.ECRI-trials.com), a non-profit organisation which received 
funding from Biosensors (Morges, Switzerland), AstraZeneca 
(Mölndal, Sweden), and The Medicines Company (Parsippany, 
NJ, USA) for the study conduct (Online Appendix 2).
The academic members of the steering committee designed the 
trial in collaboration with an independent statistician (Peter Jüni, 
Bern, Switzerland). The steering committee, together with an 
operations committee and academic representatives from ECRI, 
will oversee the medical, scientific, and operational conduct of the 
study. The steering committee members are responsible for the 
reporting of the results and the drafting and editing of this and 
forthcoming manuscripts.
An independent data and safety monitoring board (DSMB) 
monitors patient safety on an ongoing basis and has access to 
unblinded data.
Site management and monitoring is performed by Cardialysis 
in Europe and Theorem in Brazil, Canada, and Singapore. 
Angiographic data (SYNTAX score) and 12-lead ECGs (post-
index PCI before discharge, three-month and two-year follow-
up) will be analysed off-line by an independent core laboratory 
(Cardialysis, Rotterdam, The Netherlands).
Data cleaning and preparation will be performed by the 
Cardialysis data management group. After database lock, the data-
base will be housed for statistical analysis at the Clinical Trials 
Unit (Department of Clinical Research, University of Bern, Bern, 
Switzerland).
The study adheres to the ethical principles of the Declaration 
of Helsinki, to specifications of the International Conference of 
Harmonization, and to Good Clinical Practice. The study under-
went approval by an ethics committee or institutional review 
board at each site.
Study design
The GLOBAL LEADERS trial is designed as a multicentre, mul-
tinational, open-label superiority randomised clinical trial. Patients 
will be randomised before intervention to the experimental or ref-
erence DAPT antithrombotic strategy (Figure 1) in a 1:1 ratio 
using a web-based system with random, permuted blocks and 
stratified by site and clinical presentation (SCAD versus ACS). 
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Design and rationale of the GLOBAL LEADERS trial
Coronary anatomy is to be known in order to assess eligibility 
for PCI before randomisation in all patients. Multiple target vessel 
interventions are allowed either within the index procedure or as 
a pre-specified, staged (within three months following the index 
PCI) procedure. Randomised treatment continues for a minimum 
of two years post index PCI procedure in all patients (in case of 
a staged procedure, for up to two years after the initial stage of 
the index procedure). Outpatient study visits are scheduled at one, 
three (safety visit), six, 12, and 18 months after the index PCI pro-
cedure, with an end-of-treatment visit at 24 months.
Patient population
The GLOBAL LEADERS trial will enrol approximately 
16,000 patients in more than 100 interventional cardiology sites 
in Europe, Asia, Brazil, Australia and Canada during a period of 
approximately 16-24 months. Inclusion and major exclusion cri-
teria are shown in Table 1 and Table 2, respectively. According 
to the “all-comers” concept, there are no restrictions as to the 
number, severity, or location of lesions, or the number of stents 
All-comers PCI population
(ACS and stable CAD patients)
(N=16,000)
Bivalirudin*-supported
BioMatrix family stent implantation
1:1 Randomisation, open-label design
Experimental treatment strategy
 ASA Ticagrelor
 1 month 24 months
  Reference treatment strategy
 ASA Ticagrelor Clopidogrel
 24 months               12 months
                          OR
  NOT ALLOWED ONLY ALLOWED
  IN STABLE IN STABLE
  PATIENTS PATIENTS
Primary endpoint (effectiveness)
Experimental treatment strategy superior to
reference treatment strategy on cumulative 2-year
composite of all-cause mortality and new Q-wave MI
IMPORTANT: In the Reference treatment strategy arm, ticagrelor is not allowed in stable patients, and 
clopidogrel must be given in combination with ASA. However, patients already on stable maintenance 
treatment with ticagrelor (or prasugrel) can continue with ticagrelor treatment (for 12 months post 
index PCI).
*In countries where available.
Figure 1. GLOBAL LEADERS study design diagram.
Table 1. Inclusion criteria.
Consecutive patients with the following inclusion criteria:
1. Age ≥18 years.
2. Patients with any clinical indication for PCI.
3. Presence of one or more coronary artery stenoses of 50% or more 
in a native coronary artery or in a saphenous venous or arterial 
bypass conduit suitable for coronary stent implantation in 
a vessel with a reference vessel diameter of at least 2.25 mm.
Table 2. Exclusion criteria.
Drug-
related
1. Known intolerance to aspirin, P2Y12 inhibitors, 
bivalirudin, stainless steel or biolimus.
2. Known intake of a strong CYP3A4 inhibitor (e.g., 
ketoconazole, clarithromycin, nefazodone, ritonavir, 
and atazanavir), as co-administration may lead to 
a substantial increase in exposure to ticagrelor.
3. Use of fibrinolytic therapy within 24 hours of PCI.
4. Known severe hepatic impairment.
Treatment-
related
5. Planned CABG as a staged procedure (hybrid) 
within 12 months of the index procedure.
6. Planned surgery within 12 months of PCI unless 
dual antiplatelet therapy is maintained throughout 
the peri-surgical period. 
7. Need for oral anticoagulation therapy. 
8. PCI for a priori known stent thrombosis.
Medical 9. Known overt major bleeding.
10. Known history of intracranial haemorrhage.
11. Known stroke from ischaemic or unknown cause 
within last 30 days.
General 12. Known pregnancy at time of randomisation.
13. Inability to provide informed consent.
14. Currently participating in another trial before 
reaching primary endpoint.
used. Key exclusion criteria are limited to study medication safety/
intolerance, stent component allergies, or planned need for sur-
gery within the six months after the index procedure. Patients with 
ST-elevation ACS treated with fibrinolysis or patients in need of 
chronic anticoagulation are deemed not eligible.
Treatment regimens and concomitant 
medications
Patients are randomly assigned to either ticagrelor combined 
with ASA ≤100 mg for one month followed by monotherapy for 
23 months or standard DAPT with clopidogrel for 12 months plus 
ASA up to 100 mg (SCAD patients), or ticagrelor standard treat-
ment for 12 months plus ASA ≤100 mg (ACS patients) followed 
by ASA monotherapy for the study duration (Figure 1). The use 
of clopidogrel is restricted to patients undergoing elective PCI for 
stable lesions (cardiac biomarker negative, no clinical signs and/or 
symptoms of ongoing myocardial ischaemia lasting >20 minutes).
DAPT is started as early as possible, and no later than two 
hours after the index procedure. Patients receiving at least one 
maintenance dose of ticagrelor or prasugrel will be allocated to 
a ticagrelor arm (either intervention or reference) upon randomi-
sation. In the case of staged PCI or in case of unplanned reinter-
vention (other than for definite stent thrombosis or ST-segment 
elevation myocardial infarction) in the study treatment arm, the 
30-day treatment period with ASA will restart at the time of the 
staged procedure or reintervention.
Patients assigned to a ticagrelor arm who have not yet 
received a loading dose of ticagrelor or prasugrel, or who have 
received a prasugrel 60 mg loading dose within five days prior 
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to randomisation, but not continued thereafter with a daily 10 
or 5 mg maintenance regimen without interruption, will receive 
a loading dose of ticagrelor of 180 mg (two 90 mg tablets). 
Otherwise, a dose of ticagrelor of 90 mg will be administered as 
the first dose. Patients assigned to clopidogrel who have not yet 
received a loading dose of clopidogrel or have not been taking 
clopidogrel or ticlopidine for ≥5 days before randomisation will 
receive a 600 mg loading dose and, otherwise, a maintenance dose 
of clopidogrel study drug as their first dose. For patients not previ-
ously having received ASA, a loading dose of 325 mg is preferred 
(160-500 mg allowed).
In case of ticagrelor discontinuation due to adverse effects other 
than bleeding (i.e., atrioventricular block, dyspnoea), patients 
should be put on a standard dose of prasugrel in both study arms.
In case of definite stent thrombosis or ST-segment elevation 
myocardial infarction (STEMI), patients will no longer need to 
adhere to the study protocol-mandated medication regimen and 
will be treated according to best clinical practice.
Patients who require oral anticoagulation after randomisation 
should be treated according to local guidelines. Triple therapy 
should only be prescribed for the shortest necessary duration with 
frequent INR measurement (target INR 2–2.5), with clopidogrel 
becoming the default P2Y12 inhibitor.
Concomitant medication/stent
The GLOBAL LEADERS trial demands uniform anticoagulation 
during the procedure and uniform stent platform use during the 
index procedure (including staged procedures) and any unplanned 
or intercurrent re-PCI.
In all patients, anticoagulation during the procedure will 
be accomplished with bivalirudin (Angiox® or Angiomax®; 
The Medicines Company, Parsippany, NJ, USA in the coun-
tries where the drug is approved) given as a bolus of 0.75 mg/
kg followed immediately by an infusion of 1.75 mg/kg/hr for 
at least the duration of the PCI, and may be continued for up 
to four hours post PCI, at which time the infusion should be 
either stopped or reduced to a dose of 0.25 mg/kg/hr for up to 
12 hours at the discretion of the investigator. Dose adjustments 
may be required according to drug labelling (i.e., renal dysfunc-
tion). Bivalirudin, when used instead of heparin with optional 
glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitors, has consistently 
demonstrated a reduction in protocol-defined major and minor 
bleeding27. The use of GP IIb/IIIa inhibitors in the GLOBAL 
LEADERS trial should be limited to bail-out situations only 
(i.e., no-reflow phenomena, giant thrombus). The use of unfrac-
tionated heparin (up to an arbitrary set maximum of 4,000 IU) 
during the index diagnostic angiogram is left to the discretion 
of the investigator.
The stent device(s) that will be used during the index procedure 
(including staging) belong to the BioMatrix™ drug-eluting stent 
family (BES; Biosensors Europe SA, Morges, Switzerland) and 
are CE-marked and commercially available. The Biolimus A9™/
BA9™-eluting stents with biodegradable polymer represent a safe 
and effective alternative to the sirolimus-eluting stents with dur-
able polymer in patients with on- and off-label indications28.
In the event of an intercurrent repeat intervention, for reasons 
beyond definite stent thrombosis and STEMI, the physician should 
adhere to the study stent and treatment strategy including one 
month of concomitant ASA ≤100 mg post PCI (including the repeat 
and unplanned procedures) in the ticagrelor monotherapy arm.
Study endpoints
The trial endpoints are listed in Table 3. The primary outcome is the 
composite of investigator-reported all-cause mortality or non-fatal, 
new Q-wave myocardial infarction (MI) identified by an independ-
ent ECG core laboratory (Cardialysis, Rotterdam, The Netherlands) 
at two years post randomisation. The rationale for choosing this 
endpoint is to have an unbiased estimate of the effect regarding irre-
versible organ damage. All-cause mortality is an objective endpoint 
and can be readily ascertained with minimal bias or need for adjudi-
cation. Similarly, the appearance of new Q-waves on 12-lead elec-
trocardiography (Minnesota Code) following PCI and myocardial 
infarction is an objective and independent predictor of future mor-
tality29. A new left bundle branch block associated with an MI will 
be considered equivalent to a new Q-wave.
Table 3. GLOBAL LEADERS endpoints.
Primary All-cause death or non-fatal, new Q-wave 
myocardial infarction.
Key secondary Investigator-reported (IR) BARC class 4 or 5 
bleeding events.
Other The composite of all-cause death, investigator-
reported (IR) non-fatal stroke, IR myocardial 
infarction, IR coronary revascularisation.
IR non-fatal stroke.
IR myocardial infarction.
IR coronary revascularisation.
IR definite stent thrombosis according to the 
Academic Research Consortium definitions30.
IR: investigator-reported
The key safety variable is any investigator-reported Bleeding 
Academic Research Consortium (BARC) class 3 or 5 bleeding 
(Online Table 1)31. BARC consensus definitions have recently been 
validated post PCI. BARC class 3 or 5 events are independently 
associated with increased one-year mortality to an extent compara-
ble to that provided by the TIMI criteria32. An independent medical 
reviewer will check the reported endpoint events for validity.
Statistics
The assumptions regarding event rate for the composite of all-
cause mortality and Q-wave MI in the reference strategy arm are 
based on actual data from the BES arm in the LEADERS trial 
at two years after the index procedure (Online Table 2). With an 
expected event rate of 5.0% within the reference treatment strat-
egy arm at two years and a two-sided type I error of 5%, we esti-
mate that a sample size of 8,000 patients per arm will provide 84% 
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Design and rationale of the GLOBAL LEADERS trial
power to detect a 20% relative risk reduction and 92% power to 
detect a 22.5% relative risk reduction of the experimental treat-
ment strategy compared with the reference treatment strategy.
Analysis of the primary composite and secondary endpoints 
will be performed according to the intention-to-treat principle of 
all randomised patients as time-to-first-event. The primary and 
all secondary endpoints will be analysed using the Mantel-Cox 
method accompanied by the log-rank test to calculate correspond-
ing p-values. Corresponding survival curves will be constructed 
using Kaplan-Meier estimates. Patients start being at risk on the 
day of their index PCI, or, if no PCI was performed, on the day 
of randomisation. Per-protocol analyses of the primary compos-
ite effectiveness endpoint and secondary safety endpoint will be 
performed as sensitivity analyses. To evaluate for consistency of 
results among subgroups of interest, exploratory subgroup analy-
ses are pre-specified (Online Appendix 1).
Landmark analyses will be performed according to two pre-
specified landmark points at 30 days and at one year (365 days), 
with RR calculated separately for events up to the landmark point 
and for events occurring after the landmark point up to two years. 
For each type of event, patients will be censored at the time of 
the first event: a patient who experienced an event contributing to 
the primary composite endpoint during the first year, for example, 
will be censored at the time of the event and excluded from the 
analysis of subsequent years after the landmark point. Landmark 
analyses will be accompanied by a test for interaction between 
treatment effect and time (before versus after the landmark point).
Demographics, baseline (including prior and current medica-
tions) and procedural characteristics will be described using counts 
and percentages if categorical, and means and SD, if continuous. 
P-values for procedural characteristics on patient-level data will be 
computed using chi-square and Fisher’s exact tests for categorical 
variables, t-tests for continuous variables, and Wilcoxon’s Mann-
Whitney U tests for non-symmetrically distributed continuous var-
iables. P-values for procedural characteristics on lesion-level data 
will be computed using generalised linear mixed models. In each 
model a random effect of patient identifier will account for multi-
ple lesions measured within patients.
Present status
The first patient in the GLOBAL LEADERS trial was enrolled in 
June 2013. By March 1, 2015, 10,000 patients had been enrolled. 
The end of enrolment is projected for September 2015.
Conclusion
The GLOBAL LEADERS trial includes minimally selected, con-
secutive patients undergoing PCI with bivalirudin and unrestricted 
use of BES. The protocol also allows for patients exposed to clopi-
dogrel/prasugrel, both as maintenance treatment and loading dose. 
Therefore, the trial will reflect the full spectrum of patients man-
aged in routine PCI practice with different clinical presentations 
(with the exception of thrombolytic and anticoagulant therapy at 
the time of randomisation), and will provide a pivotal comparison 
of the efficacy and safety of a short course of ticagrelor plus aspi-
rin followed by 23-month ticagrelor monotherapy versus the con-
temporary standard-of-care DAPT regimen.
The GLOBAL LEADERS trial challenges the concept that, 
against the background of ticagrelor, ongoing aspirin treatment, 
beyond the initial one month time period of high stent thrombo-
sis risk, is well serving. More potent, more consistent antiplatelet 
inhibition with ticagrelor may be a better foundation for long-
term antiplatelet therapy compared to aspirin in at-risk patients. 
GLOBAL LEADERS will also provide preliminary 30-day effi-
cacy and safety data on a randomised comparison of ticagrelor 
plus low-dose aspirin versus clopidogrel and aspirin following 
DES use in a cohort of stable CAD patients. The GLOBAL 
LEADERS trial may pave the way for future studies of ticagre-
lor as antiplatelet monotherapy across a wide spectrum of patients 
with CAD and is the first large-scale study on ticagrelor in elec-
tive stenting.
Impact on daily practice
The GLOBAL LEADERS trial challenges the concept that, 
against the background of ticagrelor, ongoing aspirin treatment 
beyond the initial one-month time period of high stent throm-
bosis risk, is well serving. The GLOBAL LEADERS trial may 
pave the way for future studies of ticagrelor as antiplatelet 
monotherapy across a wide spectrum of patients with coronary 
artery disease and is the first large-scale study on ticagrelor in 
elective coronary artery stenting.
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Online Appendix 1
PRE-SPECIFIED SUBGROUP ANALYSES OF THE PRIMARY 
ENDPOINT ACCORDING TO SPECIFIC ANGIOGRAPHIC AND 
CLINICAL RISK ESTIMATES
We will check for interactions with treatment regimen towards 
cardiovascular efficacy and safety outcomes on the following 
items:
CLINICAL PRESENTATION
 1. Treatment regimen in relation to clinical presentation (acute 
coronary syndrome vs. stable, elective) overall.
 2. Treatment regimen in relation to clinical presentation 
(ST-segment elevation ACS, non-STE ACS) overall.
 3. Treatment regimen in relation to clinical presentation and 
angiographic risk profile (ST ACS vs. SYNTAX score >8) 
overall.
 4. Treatment regimen in stable patients up to 30 days, 30 days to 
end of trial (30-day landmark).
 5. Treatment regimen in relation to ECG changes at presentation.
CONCOMITANT DISEASE/BASELINE RISK FACTORS
 6. Treatment regimen in relation to renal function (and dialysis) 
at time of randomisation.
 7. Treatment regimen in relation to diabetes (type 1 & 2) status 
at randomisation.
 8. Treatment regimen in relation to weight (body mass index 
≥27) at the time of randomisation.
 9. Treatment regimen in relation to age at the time of randomi-
sation.
 10. Treatment regimen in relation to gender.
 11. Treatment regimen in relation to history of cardiovascular (car-
diac, peripheral, or combined) disease (including coronary 
artery bypass grafting).
 12. Treatment regimen in relation to history of prior stroke or 
transient ischaemic attack.
 13. Treatment regimen in relation to the GRACE risk score at 
admission.
 14. Treatment regimen in relation to the SYNTAX score (I & II) 
at admission. Including: value of incorporating baseline ECG 
changes into the SYNTAX I and II scores. Including: impact 
of residual (after PCI) SYNTAX score with respect to treat-
ment effect and outcomes.
 15. Impact of CRUSADE and or ACUITY bleeding scores in risk 
stratifying bleeding and ischaemic events and its interaction 
with treatment strategies.
GEOGRAPHIC REGION
 16. Treatment regimen in relation to geographic region (region-
by-treatment interaction) prospectively defined as South 
America, Canada, Europe, Asia.
TREATMENT ELEMENTS
DRUG
 17. Treatment regimen in relation to the access site used during 
the index procedure.
 18. Treatment regimen in relation to periprocedural anticoagula-
tion. Including: safety and efficacy of switching strategies on 
anticoagulation before and during the procedure.
 19. Treatment regimen and outcome in patients in need of 
CABG.
 20. Treatment regimen and outcome in patients with non-cardiac 
surgery.
 21. Treatment regimen in relation to previous exposure to aspi-
rin and/or P2Y12 receptor blocker (vs. naïve patients). The 
ONSET study. Including: safety and efficacy of switching 
strategies with respect to P2Y12 inhibition before PCI.
 22. Treatment regimen in relation to proton pump inhibitor use.
 23. Treatment regimen in relation to post-procedure anticoagula-
tion.
STENT PROCEDURE
 24. Treatment regimen in relation to staged procedures.
 25. Treatment regimen in relation to specific lesion subsets 
including:
a. Left main
b. Bifurcations
ANALYSIS
 26. Treatment regimen with a landmark analysis at 12 months.
 27. BARC bleeding analysis including case fatality hazard.
 28. OFFSET trial. Treatment regimen in relation to prolonged 
follow-up.
 29. Treatment regimen in relation to repeat events (including 
bleeding).
Online Appendix 2
STEERING COMMITTEE
VOTING:
P.W. Serruys (chair)
S. Windecker (co-principal investigator)
M. Valgimigli (co-principal investigator)
P. Vranckx (co-principal investigator)
P.G. Steg
C. Hamm
G.A. van Es (ECRI)
P. Jüni (statistician)
CORE LABORATORY
ANGIOGRAPHY:
An independent angiographic core laboratory, located at Cardialysis, 
Rotterdam, The Netherlands, will analyse all diagnostic angiograms 
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and define the SYNTAX score blinded to the therapy. Members of 
the angiographic core laboratory are not involved as investigators or 
co-investigators in this study.
ECG:
ECGs will be collected according to the schedule of investigations 
and will be assessed by an independent core laboratory, located at 
Cardialysis, Rotterdam, The Netherlands.
DATA SAFETY AND MONITORING BOARD:
F.W.A. Verheugt, Onze Lieve Vrouw Gasthuis, Amsterdam, 
The Netherlands (Chairman)
J.G.P.Tijssen, Academic Medical Center, Amsterdam, 
The Netherlands (Biostatistician)
L. Mauri, Brigham and Women’s Hospital, Boston, USA.
BLINDED INDEPENDENT MEDICAL REVISOR:
E. McFadden, Cork University Hospital, Cork, Ireland.
DATA MONITORING:
CARDIALYSIS
92 Westblaak, 3012 KM Rotterdam, The Netherlands.
THEOREM
1016 West Ninth Avenue, King of Prussia, PA, 19406, USA.
SPONSOR:
The European Cardiovascular Research Institute 
(ECRI; www.ECRI-trials.com)
Online Table 1. BARC class 3 and 5 bleeding criteria.
Type 3A Overt bleeding plus haemoglobin drop of 3 to <5 g/dL* 
(provided haemoglobin drop is related to bleed)
Any transfusion with overt bleeding
Type 3B Overt bleeding plus haemoglobin drop ≥5 g/dL* 
(provided haemoglobin drop is related to bleed)
Cardiac tamponade
Bleeding requiring surgical intervention for control 
(excluding dental/nasal/skin/haemorrhoid)
Bleeding requiring intravenous vasoactive agents
Type 3C Intracranial haemorrhage (does not include micro-bleeds 
or haemorrhagic transformation, does include intra-spinal)
Subcategories confirmed by autopsy or imaging or 
lumbar puncture
Intraocular bleed compromising vision
Type 5A Probable fatal bleeding: no autopsy or imaging 
confirmation but clinically suspicious
Type 5B Definite fatal bleeding; overt bleeding or autopsy or 
imaging confirmation
* Corrected for transfusion (1 U packed red blood cells or 1 U whole 
blood=1 g/dL haemoglobin).
Online Table 2. Power calculation.
With an expected event rate of 5.0% within the experimental 
treatment strategy at two years and a two-sided type I error of 5%, 
we estimate that the sample size of 8,000 patients per arm will 
provide 84% power to detect a 20% relative risk reduction and 92% 
power to detect a 22.5% relative risk reduction of the experimental 
treatment strategy as compared with the control treatment strategy. 
The table below presents the power according to relative risk 
reductions of 17.5%, 20%, 22.5%, and 25%, respectively:
Treatment effect 
(%)
Power (%)
Attrition rate 
(%)
Total sample 
size
17.5 73 4 16,000
20.0 84 4 16,000
22.5 92 4 16,000
25.0 96 4 16,000
